Noticeably, subgroup analyses of the PARADIGM-HF and PARAMOUNT-HF trials all found that sacubitril-valsartan could delay the progression of renal function deterioration in HFrEF or HFpEF patients compared to renin–angiotensin–aldosterone system (RAAS) inhibitors, although there was a modest increase in the urinary albumin/creatinine ratio (UACR) after 8 months. Here, REN is linked to hydrops fetalis.